Freyja Healthcare, LLC announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for VereSee™, the company's second-generation Mini Laparoscope with VisualEntry™ System. This clearance marks a significant milestone for the company, which aims to advance visualization at the earliest stages of minimally invasive surgery.
VereSee is designed to bring direct visualization to laparoscopic entry, combining a miniature 2mm laparoscope with Freyja's VisualEntry™ System. By allowing surgeons to see anatomy during the entry process, VereSee introduces a new approach to one of the most critical steps in laparoscopic surgery. Traditionally, initial abdominal access may be performed without direct visualization, but VereSee is built on the concept of providing sight during entry rather than after access is established. Once access is achieved, the device can also serve as a functional miniature laparoscope, potentially eliminating the need for an additional scope in certain procedures.
"FDA clearance of VereSee is an incredibly important milestone for Freyja Healthcare," said Mike MacKinnon, CEO of Freyja Healthcare. "We believe surgeons should have the ability to see when it matters most. VereSee brings visualization to the very beginning of the procedure while also providing the functionality of a miniature laparoscope, which may enable surgeons to avoid opening an additional laparoscope for certain procedures."
The system pairs single-use entry components with reusable visualization technology, creating a platform that fits naturally into the laparoscopic workflow while supporting a practical healthcare economic model. VereSee was reviewed under the FDA's 510(k) premarket notification pathway and is classified as a Class II Endoscope and Accessories device.
"VereSee represents more than a new method of laparoscopic entry," said Jon I. Einarsson, MD, founder of Freyja Healthcare. "It is a miniature laparoscopic visualization platform that gives surgeons the opportunity to see anatomy from the moment of entry. We believe that has the potential to fundamentally change how surgeons think about access, while continuing to advance the miniaturization of laparoscopic visualization and scope functionality."
With FDA clearance achieved, Freyja Healthcare will begin commercial introduction of VereSee and expand access to the technology among hospitals, ambulatory surgical centers, and surgeons performing minimally invasive procedures. This clearance not only validates the company's innovative approach but also underscores the growing trend toward enhanced visualization and miniaturization in surgical tools, which could lead to improved patient outcomes and procedural efficiency.
The implications of this clearance extend beyond Freyja Healthcare. By enabling visualization during entry, VereSee may reduce the risk of complications associated with blind entry, such as vascular or bowel injury. Furthermore, the ability to use the same device for both entry and visualization could streamline procedures, reduce the number of instruments needed, and potentially lower healthcare costs. As minimally invasive surgery continues to evolve, innovations like VereSee are poised to set new standards for safety and efficiency, ultimately benefiting patients and healthcare systems alike.
